Future Trends in Demand for Liver Transplant: Birth Cohort Effects Among Patients With NASH and HCC
- PMID: 30451739
- DOI: 10.1097/TP.0000000000002497
Future Trends in Demand for Liver Transplant: Birth Cohort Effects Among Patients With NASH and HCC
Abstract
Background: With increasing US adiposity, nonalcoholic steatohepatitis (NASH) is now a leading liver transplant (LT) indication. Given its association with hepatocellular carcinoma (HCC), the burden of NASH is substantial. We analyzed birth cohort effects among NASH LT registrants, with and without HCC.
Methods: All new LT registrants in United Network for Organ Sharing (1995-2015) were identified. Birth cohorts were defined as: 1936-1940, 1941-1945, 1946-1950, 1951-1955, 1956-1960, 1961-1965, 1966-1970, 1971-2015. Poisson regression examined trends in LT registration, by disease etiology (NASH, hepatitis C virus [HCV], other liver disease etiologies [OTHER]), and HCC.
Results: We identified 182 368 LT registrants with median age of 52 years (range, 0-86 years). Nine percent (n = 16 160) had NASH, 38% (n= 69 004) HCV, 53% (n = 97 204) OTHER. HCC was present in: 13% (n = 2181), 27% (n = 18 295), and 11% (n = 10 902), of NASH, HCV, and OTHER, respectively. Liver transplant registration for HCC increased significantly from 2002 to 2015 across all etiologies (NASH, 6%-18%; HCV, 19%-51%; OTHER, 9%-16%; P < 0.0001 for all). NASH LT registrations, with and without HCC, increased sharply in patients born from 1945 to 2015. This upward NASH trend is in stark contrast to HCV LT registrations, which showed a general decline. Notably, a sharp rise in LT registrations is occurring among younger NASH patients (35-55 years), mirroring the increasing adiposity across all age groups in the US population.
Conclusions: NASH LT registrants, with and without HCC, have increased over time, and are projected to increase unabated in the future, notably among younger birth cohorts ("Adipose Wave Effect"). HCC LT registration patterns demonstrate that, compared with HCV, NASH patients encompass younger birth cohorts. These data illustrate that the full impact of NASH on demand for LT is yet to be realized.
Comment in
-
Liver Transplantation for Nonalcoholic Steatohepatitis: New Evidence of a Profound Increase Across Age Cohorts.Transplantation. 2019 Jan;103(1):1-2. doi: 10.1097/TP.0000000000002513. Transplantation. 2019. PMID: 30399124 No abstract available.
Similar articles
-
Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma.Liver Transpl. 2012 Dec;18(12):1471-8. doi: 10.1002/lt.23551. Liver Transpl. 2012. PMID: 23008049 Free PMC article.
-
NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances.Am J Gastroenterol. 2018 Nov;113(11):1649-1659. doi: 10.1038/s41395-018-0088-6. Epub 2018 Jun 8. Am J Gastroenterol. 2018. PMID: 29880964 Free PMC article.
-
Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.Liver Transpl. 2016 Oct;22(10):1356-66. doi: 10.1002/lt.24507. Liver Transpl. 2016. PMID: 27348270
-
Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.Expert Rev Gastroenterol Hepatol. 2019 Feb;13(2):179-187. doi: 10.1080/17474124.2019.1549989. Epub 2018 Dec 29. Expert Rev Gastroenterol Hepatol. 2019. PMID: 30791782 Review.
-
Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.Clin J Gastroenterol. 2015 Feb;8(1):1-9. doi: 10.1007/s12328-014-0548-5. Epub 2015 Jan 10. Clin J Gastroenterol. 2015. PMID: 25575848 Review.
Cited by
-
Temporal Trends in Portopulmonary Hypertension Model for End-stage Liver Disease Exceptions and Outcomes.Transplant Direct. 2022 Nov 11;8(12):e1410. doi: 10.1097/TXD.0000000000001410. eCollection 2022 Dec. Transplant Direct. 2022. PMID: 36398194 Free PMC article.
-
Global research trends on gut microbiota and metabolic dysfunction-associated steatohepatitis: Insights from bibliometric and scientometric analysis.Front Pharmacol. 2024 Jul 11;15:1390483. doi: 10.3389/fphar.2024.1390483. eCollection 2024. Front Pharmacol. 2024. PMID: 39070791 Free PMC article.
-
Preparation and Characterization of a Liver Targeted, Poly(amidoamine) Based, Gene Delivery System.Methods Mol Biol. 2022;2455:319-332. doi: 10.1007/978-1-0716-2128-8_24. Methods Mol Biol. 2022. PMID: 35213004 Free PMC article.
-
Perspectives on youth-onset nonalcoholic fatty liver disease.Endocrinol Diabetes Metab. 2020 Sep 17;3(4):e00184. doi: 10.1002/edm2.184. eCollection 2020 Oct. Endocrinol Diabetes Metab. 2020. PMID: 33102800 Free PMC article. Review.
-
Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges.Dig Dis Sci. 2019 Dec;64(12):3413-3430. doi: 10.1007/s10620-019-05716-1. Epub 2019 Jul 16. Dig Dis Sci. 2019. PMID: 31312990 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical